BioSpace News Archive

National medical flight charity Miracle Flights announces partnership with Perthes Kids Foundation, founded by Survivor winner Earl Cole, to fly kids with rare condition to life-changing camp for free

“We are thrilled that Reba, Carrah, Keisha, and Rob will join our board,” said Foundation CEO and President Kevin Lynch.

Healthier alternatives of repairing teeth are available, learn more about Supra-gingival Dentistry

EVERSANA™, the leading independent provider of global services to the life science industry, today announced three appointments to the executive leadership team.

Intelligent Lab, Chromatography, Particle Sizer Analytical Technology, and New Product Recommendation, and gather government agency, senior industry association, leading pharmaceutical enterprise, well-known medical institution, and professional research institution and R&D institution to discuss industry hotspots and specialized topics.

Company remains committed to investing in proprietary computational discovery platform and advancing its early stage immuno-oncology pipeline

Eyecarrot Innovations Corp is pleased to announce it has secured a distribution deal with Europe’s leading vision rehabilitation distribution organization VISUS ® Contactlinsen GmbH.

The first two webinars in AMPLEXOR Life Sciences’ 2019 webinar program have been announced, focusing on “Regulatory Information Management: Delivering Better Efficiencies Across Operations” and “Ensuring Compliance for Pharma Companies Through Local Label Deviations.”

Neovasc Inc. announced the pricing of its previously announced underwritten public offering of 11,111,111 common shares of the Company at a price to the public of US$0.45 per Common Share, for aggregate gross proceeds to the Company of approximately US$5 million, before deducting the underwriting commission and estimated Offering expenses payable by the Company.

Axonics Modulation Technologies, Inc. announced the submission of pivotal clinical data from the ARTISAN-SNM pivotal clinical study designed to gain marketing approval from the U.S. Food & Drug Administration for the Axonics r-SNM® System1.